Assembly Biosciences, Inc.: 10-Q filed 2014-11-17
What Assembly Biosciences, Inc. reported in its quarterly report filed 2014-11-17 (fiscal Q3 2014): 24 published measures, 59 facts as tagged in accession 0001144204-14-069040.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-11-17
- Fiscal period
- fiscal Q3 2014
- Accession
- 0001144204-14-069040 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Assembly Biosciences, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 60,393,941 | USD | |
| At 2013-12-31 | 27,132,042 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 13,191,721 | USD | |
| At 2013-12-31 | 2,638,054 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 47,202,220 | USD | |
| At 2013-12-31 | 24,493,988 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 17,932,627 | USD | |
| At 2013-12-31 | 27,061,268 | USD | |
| At 2013-09-30 | 32,222,910 | USD | |
| At 2012-12-31 | 20,489,219 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-09-30 | -11,020,258 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -17,559,448 | USD | 273 |
| 2013-07-01 to 2013-09-30 | -4,881,742 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -13,356,725 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-09-30 | -11,380,582 | USD | 273 |
| 2013-01-01 to 2013-09-30 | -12,403,656 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-09-30 | 20,526 | USD | 273 |
| 2013-01-01 to 2013-09-30 | 5,166 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-09-30 | 1,763,104 | USD | 273 |
| 2013-01-01 to 2013-09-30 | 24,142,513 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-09-30 | 488,837 | USD | 273 |
| 2013-01-01 to 2013-09-30 | -5,166 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | -129,282,721 | USD | |
| At 2013-12-31 | -111,723,273 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 34,084 | USD | |
| At 2013-12-31 | 7,102 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-09-30 | 8,002,033 | USD | 273 |
| 2013-01-01 to 2013-09-30 | 1,451,688 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-09-30 | -11,055,440 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -17,671,735 | USD | 273 |
| 2013-07-01 to 2013-09-30 | -4,933,008 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -13,510,734 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 18,079,805 | USD | |
| At 2013-12-31 | 27,124,940 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 1,049,019 | USD | |
| At 2013-12-31 | 2,638,054 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 12,142,702 | USD | |
| At 2013-12-31 | 0 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 30,137,350 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-09-30 | 3,671,983 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 7,741,317 | USD | 273 |
| 2013-07-01 to 2013-09-30 | 3,753,319 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 9,870,871 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 8,688,099 | shares | |
| At 2013-12-31 | 4,146,779 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 176,107,503 | USD | |
| At 2013-12-31 | 135,844,320 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 30,137,350 | USD | |
| At 2013-12-31 | 0 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-09-30 | 7,383,457 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 9,930,418 | USD | 273 |
| 2013-07-01 to 2013-09-30 | 1,179,689 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 3,639,863 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-09-30 | 3,894 | USD | 273 |
| 2013-01-01 to 2013-09-30 | 4,375 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-09-30 | 35,182 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 112,287 | USD | 273 |
| 2013-07-01 to 2013-09-30 | 51,266 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 154,009 | USD | 273 |
Inspect the source
- Entity
- Assembly Biosciences, Inc. / CIK 0001426800
- Captured
- 2026-09-20T08:03:55.156Z
- SEC response SHA-256
f87ee3d44f43bd73d30c280e8d97b2de4bcc4d8a35b03fbebb0e715c83069335
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001426800.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))